Monsel's Solution: A Brief History.
Explore the source record for details and available documents.
Journal Article↗
Biomedical subjects
Audrey P Garrett
Publications and source records attributed to Audrey P Garrett.
Can Monsel's Transmit Nosocomial Infections? A Microbiological Investigation.
OBJECTIVE.: Our objective was to test whether common nosocomial pathogenic bacteria can be cultured in Monsel's paste, 20% ferric subsulfate, an astringent solution with styptic qualities that causes hemostasis when applied topically to small cuts. MATERIALS AND METHODS.: First, samples of Monsel's paste were collected and plated onto 4 media. Bacterial growth was evaluated at 48 hours. Second, thioglycollate medium was inoculated with a combination of Monsel's paste and actively growing stock bacteria. After 2 days, the samples were subcultured. They were evaluated for growth at 5 days. Next, samples of Monsel's were inoculated with 10Pseudomonas aeruginosa or 10Clostridium perfringens. The samples of inoculated paste were examined at 5-minute intervals thereafter to evaluate bacterial survival. RESULTS.: Neither the open samples of Monsel's solution nor the inoculated samples of Monsel's solution grew bacteria. When the samples inoculated with 10 organisms were examined at timed intervals after inoculation, no bacteria were noted after 5 minutes. CONCLUSIONS.: It is unlikely that nosocomial bacteria could survive exposure to Monsel's solution. Thus, potential contamination of the solution is unlikely, and subsequent transmission of infection is improbable.
Journal Article↗
Methotrexate infusion and folinic acid as primary therapy for nonmetastatic and low-risk metastatic gestational trophoblastic tumors. 15 years of experience.
OBJECTIVE: To investigate the efficacy and toxicity of methotrexate (MTX) given intravenously (i.v.) at a dose of 100 mg/m2 i.v. bolus and 200 mg/m2 infusion over 12 hours followed by folinic acid in the primary treatment of gestational trophoblastic tumors (GTTs). STUDY DESIGN: We reviewed the records of patients at the New England Trophoblastic Disease Center who had received MTX infusion at a dose of 100 mg/m2 i.v. bolus and 200 mg/m2 infusion over 12 hours followed by folinic acid as primary therapy for GTTs that did not resolve with uterine evacuation alone. Data on the patients' age, gravity and parity, disease stage (by FIGO and WHO criteria), antecedent pregnancy, presenting level of hCG, metastatic status, courses of chemotherapy required to achieve remission, toxicity related to chemotherapy treatments and time to normalization of hCG were recorded. RESULTS: One hundred ninety-two patients with persistent GTTs were treated with the MTX infusion protocol between December 1985 and December 2000. One hundred twenty-four patients (64.6%) achieved complete remission with the MTX infusion protocol. Complete remission was induced in 108 (87.1%) with a single course of chemotherapy; 12 others achieved remission with a single additional course of MTX. All patients found to be resistant to MTX therapy later achieved remission with other chemotherapy. Minimal toxicity was experienced during MTX treatment. CONCLUSION: MTX infusion with folinic acid is effective and well tolerated as primary single-agent therapy for nonmetastatic and low-risk metastatic GTT.
Administration, Oral↗